=ACADIA Pharmaceuticals (ACAD) reported earnings on Tue 8 Aug 2017 (a/h)

ACADIA Pharmaceuticals beats by $0.17, beats on revs

• Reports Q2 (Jun) loss of $0.55 per share, $0.17 better thanthe Capital IQ Consensus of ($0.72); revenues rose 30400.0% year/year to $30.5 mln vs the $20.02 mln Capital IQ Consensus. 
• Recent Highlights Conducted End-of-Phase II meeting with the FDA on the Alzheimer's disease psychosis (AD Psychosis) program. Abstract of Phase II data with pimavanserin for AD Psychosis was accepted for presentation at the Clinical Trials on Alzheimer's Disease meeting in early November 2017.